NET Recovery

NET Recovery operates across medical devices, health care, and clinical trials, with a focused offering in non-pharmacological support for substance withdrawal. Its NET Device™ uses transcranial alternating current stimulation and adhesive electrodes placed behind the ears; the company describes the device as FDA-cleared for reducing opioid withdrawal symptoms. Its Miami service combines device use with professional monitoring and check-ins, positioning the company as both a device developer and a direct treatment provider rather than solely a hardware supplier. The company also received FDA breakthrough device designation in September 2026 for an investigational use related to psychostimulant addiction, which is distinct from clearance for its opioid-withdrawal use and does not authorize the investigational indication. Its differentiation therefore rests on its stimulation-based device, care model, and developing evidence base.

Founded in 2018, NET Recovery has progressed from early-stage financing toward clinical development and direct service delivery. It raised three seed rounds between June 2021 and December 2022, totaling $1.21 million, followed by two venture rounds in 2023 totaling $695,000. The latest recorded round was $500,000 on October 2, 2023; the five rounds sum to $1.905 million. A clinical study announced on October 21, 2025, reported that the neurostimulation device may reduce both opioid and stimulant use, providing a potential evidence inflection point, although the announcement alone does not establish clinical effectiveness. In 2026, the company described a Miami private-pay treatment service, and on September 23 it received FDA breakthrough device designation for an investigational psychostimulant-addiction use. Together, these steps suggest a shift from device development and trials toward service delivery and exploration of an additional indication. With no funding recorded after 2023, the pace and resourcing of further expansion remain unclear.